Cargando…

PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve

BACKGROUND: Survivors of myocardial infarction (MI) are at high risk of new major adverse cardiovascular events (MACE). Coronary flow reserve (CFR) is a strong and independent predictor of MACE. Understanding the prevalence of impaired CFR in this patient group and identifying risk markers for impai...

Descripción completa

Detalles Bibliográficos
Autores principales: Haraldsson, Inger, Gan, Li-Ming, Svedlund, Sara, Torngren, Kristina, Westergren, Helena U, Redfors, Björn, Lagerström-Fermér, Maria, Angerås, Oskar, Råmunddal, Truls, Petursson, Petur, Odenstedt, Jacob, Albertsson, Per, Erlinge, David, Omerovic, Elmir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718055/
https://www.ncbi.nlm.nih.gov/pubmed/31695398
http://dx.doi.org/10.2147/VHRM.S209003
_version_ 1783447672676417536
author Haraldsson, Inger
Gan, Li-Ming
Svedlund, Sara
Torngren, Kristina
Westergren, Helena U
Redfors, Björn
Lagerström-Fermér, Maria
Angerås, Oskar
Råmunddal, Truls
Petursson, Petur
Odenstedt, Jacob
Albertsson, Per
Erlinge, David
Omerovic, Elmir
author_facet Haraldsson, Inger
Gan, Li-Ming
Svedlund, Sara
Torngren, Kristina
Westergren, Helena U
Redfors, Björn
Lagerström-Fermér, Maria
Angerås, Oskar
Råmunddal, Truls
Petursson, Petur
Odenstedt, Jacob
Albertsson, Per
Erlinge, David
Omerovic, Elmir
author_sort Haraldsson, Inger
collection PubMed
description BACKGROUND: Survivors of myocardial infarction (MI) are at high risk of new major adverse cardiovascular events (MACE). Coronary flow reserve (CFR) is a strong and independent predictor of MACE. Understanding the prevalence of impaired CFR in this patient group and identifying risk markers for impaired CFR are important steps in the development of personalized and targeted treatment for high-risk individuals with prior MI. METHODS: PROFLOW is a prospective, exploratory, cross-sectional open study. We used information from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) to identify high-risk patients with a history of type-1 MI. We measured CFR non-invasively in a left anterior descending artery (LAD) using transthoracic Doppler echocardiography. Coronary flow velocity was measured at rest and at maximal flow after induction of hyperemia by intravenous infusion of adenosine (140 μg/kg/min). Independent predictors of CFR were assessed with multiple linear regression. RESULTS: We included 619 patients. The median age was 69 (IQR 65–73), and 114 (18.4%) were women. Almost one-half of the patients, 285 (46.0%) had the multi-vessel disease, and 147 (23.7%) were incompletely revascularized. The majority were on optimal standard treatment eg ASA (93.1%), statins (90.0%), ACEI/ARB (82.6%) and beta-blockers (80.8%). The majority, 547 (88.4%) had no angina pectoris, and 572 (92.2%) were in NYHA class I. Evaluation of CFR was possible in 611 (98.7%) patients. Mean CFR was 2.74 (±0.79 (mean ± SD)). A substantial number of patients (39.7%) had CFR ≤2.5. In a multiple linear regression model age, dyslipidemia, smoking, hypertension, body mass index, incomplete revascularization, and treatment with angiotensin receptor blockers were independent predictors of CFR. CONCLUSION: In this high-risk group of patients with prior MI, the prevalence of impaired CFR was high. Further risk stratification with CFR in addition to traditional cardiovascular risk factors may improve predictive accuracy for future MACE in this patient population.
format Online
Article
Text
id pubmed-6718055
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67180552019-11-06 PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve Haraldsson, Inger Gan, Li-Ming Svedlund, Sara Torngren, Kristina Westergren, Helena U Redfors, Björn Lagerström-Fermér, Maria Angerås, Oskar Råmunddal, Truls Petursson, Petur Odenstedt, Jacob Albertsson, Per Erlinge, David Omerovic, Elmir Vasc Health Risk Manag Original Research BACKGROUND: Survivors of myocardial infarction (MI) are at high risk of new major adverse cardiovascular events (MACE). Coronary flow reserve (CFR) is a strong and independent predictor of MACE. Understanding the prevalence of impaired CFR in this patient group and identifying risk markers for impaired CFR are important steps in the development of personalized and targeted treatment for high-risk individuals with prior MI. METHODS: PROFLOW is a prospective, exploratory, cross-sectional open study. We used information from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) to identify high-risk patients with a history of type-1 MI. We measured CFR non-invasively in a left anterior descending artery (LAD) using transthoracic Doppler echocardiography. Coronary flow velocity was measured at rest and at maximal flow after induction of hyperemia by intravenous infusion of adenosine (140 μg/kg/min). Independent predictors of CFR were assessed with multiple linear regression. RESULTS: We included 619 patients. The median age was 69 (IQR 65–73), and 114 (18.4%) were women. Almost one-half of the patients, 285 (46.0%) had the multi-vessel disease, and 147 (23.7%) were incompletely revascularized. The majority were on optimal standard treatment eg ASA (93.1%), statins (90.0%), ACEI/ARB (82.6%) and beta-blockers (80.8%). The majority, 547 (88.4%) had no angina pectoris, and 572 (92.2%) were in NYHA class I. Evaluation of CFR was possible in 611 (98.7%) patients. Mean CFR was 2.74 (±0.79 (mean ± SD)). A substantial number of patients (39.7%) had CFR ≤2.5. In a multiple linear regression model age, dyslipidemia, smoking, hypertension, body mass index, incomplete revascularization, and treatment with angiotensin receptor blockers were independent predictors of CFR. CONCLUSION: In this high-risk group of patients with prior MI, the prevalence of impaired CFR was high. Further risk stratification with CFR in addition to traditional cardiovascular risk factors may improve predictive accuracy for future MACE in this patient population. Dove 2019-08-28 /pmc/articles/PMC6718055/ /pubmed/31695398 http://dx.doi.org/10.2147/VHRM.S209003 Text en © 2019 Haraldsson et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Haraldsson, Inger
Gan, Li-Ming
Svedlund, Sara
Torngren, Kristina
Westergren, Helena U
Redfors, Björn
Lagerström-Fermér, Maria
Angerås, Oskar
Råmunddal, Truls
Petursson, Petur
Odenstedt, Jacob
Albertsson, Per
Erlinge, David
Omerovic, Elmir
PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
title PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
title_full PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
title_fullStr PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
title_full_unstemmed PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
title_short PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
title_sort prospective evaluation of coronary flow reserve and molecular biomarkers in patients with established coronary artery disease the proflow-trial: cross-sectional evaluation of coronary flow reserve
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718055/
https://www.ncbi.nlm.nih.gov/pubmed/31695398
http://dx.doi.org/10.2147/VHRM.S209003
work_keys_str_mv AT haraldssoninger prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT ganliming prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT svedlundsara prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT torngrenkristina prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT westergrenhelenau prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT redforsbjorn prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT lagerstromfermermaria prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT angerasoskar prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT ramunddaltruls prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT peturssonpetur prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT odenstedtjacob prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT albertssonper prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT erlingedavid prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve
AT omerovicelmir prospectiveevaluationofcoronaryflowreserveandmolecularbiomarkersinpatientswithestablishedcoronaryarterydiseasetheproflowtrialcrosssectionalevaluationofcoronaryflowreserve